An Exploratory Multicenter, Double-Blind, Diphenhydramine- and Placebo-Controlled Safety, Efficacy and Biomarker Study With JNJ-42847922 in Subjects With Major Depressive Disorder

Trial Profile

An Exploratory Multicenter, Double-Blind, Diphenhydramine- and Placebo-Controlled Safety, Efficacy and Biomarker Study With JNJ-42847922 in Subjects With Major Depressive Disorder

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Seltorexant (Primary) ; Diphenhydramine
  • Indications Major depressive disorder
  • Focus Adverse reactions
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Jun 2016 Data from this trial will be presented at the Jefferies 2016 Healthcare Conference, according to a Minerva Neurosciences media release.
    • 11 Mar 2016 According to a Minerva Neurosciences media release, based on the results of this trial, the company plans to initiate another phase IIb study of MIN-202 (see CTP 700269173).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top